Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis

Journal of the Medical Association of Thailand

Volumn 85, Issue 11, 2002, Pages 1204-1209

  Ruangjutipopan, Sutat ^a   Louthrenoo, Worawit ^a   Wichainun, Ramjai ^a   Kasitanon, Nuntana ^a   Sukitawut, Waraporn ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Causes of death; Prognostic factor; Scleroderma; Survival rate; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; PROGNOSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; THAILAND;

ADULT; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THAILAND;

EID: 0036880982     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. th ed., Boston: Little Brown and Co, 1998: 1459-99.
2. rd ed., Philadelphia: Lea & Febiger, 1997: 1433-64.
3. Silman AJ. Mortality from scleroderma in England and Wales, 1968-1985. Ann Rheum Dis 1991; 50: 95-6.
4. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: A comparison with the general population. J Rheumatol 1995; 22: 2100-2.
5. Czirjak L, Nagy Z, Szegedi G. Survival analysis of 118 patients with systemic sclerosis. J Intern Med 1993; 234: 335-7.
6. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15: 276-83.
7. Jacobsen S, Halgberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). BrJ Rheumatol 1998; 37: 750-5.
8. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993; 36: 460-4.
9. Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 1985; 28: 1336-40.
10. Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: An epidemiological study. Ann Rheum Dis 1993; 52: 531-3.
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of The American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
12. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: Using a modified Medsger scale. Ann Rheum Dis 2001; 60: 1117-22.
13. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
14. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 139-48.
15. Simeon CP, Armadans L, Fonollosa V, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 723-8.
16. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus lowdose trial. Arthritis Rheum 2000; 43: 2445-54.
17. Altman RD, Medsger Jr TA, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
18. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
19. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 37: 1122-6.
20. Medsger Jr TA, Masi TA, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-76.
21. Medsger Jr TA, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and dermographic factors in 358 male US. veteran patients. J Chronic Dis 1973; 26: 647-60.
22. Steen VD, Medsger Jr TA, Osial Jr TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779-86.
23. Kostis JB, Seibold JR, Turkevich D, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988; 84: 1007-15.
24. Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in scleroderma. Ann Rheum Dis 1971; 30: 581-8.
25. Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 9: 1283-9.
26. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995; 54: 853-5.
27. Norasetthada A, Louthrenoo W, Sukitawut W. Macrovascular diseases in scleroderma. A report of three cases and review of the literature. Intern Med (Thailand) 1997; 13: 62-5.
28. Steen VD, Powell DL, Medsger Jr TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
29. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.